Navigation Links
Deloitte Recap Launches New Series of Biopharmaceutical Business Intelligence Tools
Date:10/8/2009

SAN FRANCISCO, Oct. 8 /PRNewswire/ -- Deloitte Recap LLC (Recap) has launched the first two products in the Recap IQ Series by Deloitte, a new subscription service that provides analytical tools built on rich databases tailored toward business development, corporate strategy, financial, legal, tax and R&D professionals. Each product within the series is designed around specific biopharmaceutical research needs to offer the right business intelligence tools for the job.

"The powerful combination of IQ Series products enables users to observe leading practices in drafting an alliance and evaluating different deal structures," said Mark Edwards, president, Deloitte Recap LLC. "Subscribers can compare deals objectively to identify critical deal terms, including market rates for royalties, transfer prices and profit splits."

The first two complementary modules of the Recap IQ Series by Deloitte are "Deal Builder" and "Valuation Analyzer," which can either be purchased separately or bundled together. "Deal Builder" is a comprehensive, fully searchable database of 30,000 biopharma and related alliances covering the past three decades, including 24,000 U.S. Securities and Exchange Commission (SEC)-filed contracts.

"Valuation Analyzer" provides access to the Recap Effective Royalty Rate (EFR) Grapher, a tool used to perform real-time searches of more than 1,500 unredacted biopharma alliances. Recap has obtained unredacted copies of these contracts via Freedom of Information Act (FOIA) requests made to the SEC. By combining this unique database with EFR analysis, Recap has pioneered the objective analysis of post-launch deal structures.

"As alliance activity continues to accelerate in the Life Sciences industry, the launch of 'Deal Builder' and 'Valuation Analyzer' helps provide Deloitte Recap subscribers of the Recap IQ Series by Deloitte with a timely resource to evaluate their alliance strategies supported by the latest industry data," said Terry Hisey, vice chairman and Life Sciences Industry Leader, Deloitte LLP. "Since the acquisition of Recombinant Capital, Inc. last July, Deloitte has worked to develop these new solutions and services to provide subscribers with flexible tools built on rich data sources."

"The Recap IQ Series by Deloitte provides users a one-stop-shopping experience for identifying the latest trends in biopharmaceutical alliance formation, as well as developing strategies for execution," said Mike McCully, senior manager, Deloitte Recap LLC. "Deloitte will continue to develop new modules to complete the series over the next year to further enhance the suite of solutions and services available to subscribers."

About Recap

Originally founded as Recombinant Capital, Inc. in 1988 by Mark Edwards and based in the San Francisco Bay Area. In July 2008, Recombinant Capital, Inc. was purchased by a subsidiary of Deloitte LLP and the business is now known as Deloitte Recap LLC (Recap). Please see www.recap.com for more information about Recap's services. As used in this document, "Recap" means Deloitte Recap LLC and "Deloitte" means Deloitte LLP and Deloitte Services LP, a subsidiary of Deloitte LLP. Please see www.deloitte.com/us/about for a detailed description of the legal structure of Deloitte LLP and its subsidiaries.

    CONTACT:
    Marykate Reese
    Public Relations
    Deloitte
    +1 203 257 0452
    mareese@deloitte.com

SOURCE Deloitte


'/>"/>
SOURCE Deloitte
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Deloitte Leadership Offers Crucial Convergence Considerations for Life Sciences Companies
2. CardioDynamics Ranked in Deloittes Technology Fast 50 Program for San Diego
3. WuXi PharmaTech (NYSE: WX) Wins Both Deloitte Technology Fast 50 China and Deloitte Technology Fast 500 Asia
4. WuXi PharmaTech (NYSE: WX) Ranked the 28th of Deloitte Technology Fast 50 China
5. Align Technology, Inc. Ranked 23rd in Deloittes Technology Fast 50 Program for Silicon Valley Scientific & Medical Equipment, and Bio-Technology Companies
6. Alma Lasers Ranked 9th in Deloitte Technology Fast 50 Award
7. Deloitte Chairman of the Board Sharon L. Allen Named Chairman of the American Friends of the Phelophepa Train
8. China Technology Appoints Deloitte Touche Tohmatsu CPA as Independent Auditor
9. As Billions in Blockbuster Drug Revenue Goes Off Patent, Life Sciences Companies are Challenged to Fundamentally Change Future R&D Strategies, According to New Deloitte Report
10. Deloitte Agrees to Acquire Recombinant Capital, A Leading Life Sciences Subscription Database and Advisory Services Firm
11. In a Year of Unprecedented Growth for Biotechnology Innovation, Targeted Therapies Gain Most Significant Traction, According to New Deloitte Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/11/2016)... ... February 11, 2016 , ... ... has announced a new agreement with Bankok,Thailand-based Global Stem Cells Network (GSCN) to ... in 15 Latin American countries, including Mexico, Costa Rica, Dominican Republic, Colombia, Argentina, ...
(Date:2/10/2016)... , February 10, 2016 Early-career researchers ... , Peru , Uganda and ... life-enhancing work in health and nutrition   Indonesia ... Uganda and Yemen are being ... and epidemiology. They are also celebrated for mentoring young women scientists who ...
(Date:2/10/2016)... ASAE is introducing a hybrid membership model which will ... of joining or renewing through an organizational purchasing model. ... every employee in any size association or AMC office ... member benefits.   John H. Graham, IV ... allow organizations of any size and their employees to ...
(Date:2/10/2016)... 2016  Allergan plc (NYSE: AGN ) a ... Saunders , Allergan,s CEO and President, will be featured ... at the RBC Capital Markets Healthcare Conference on Tuesday, ... New York Palace Hotel in New York, ... and can be accessed on Allergan,s Investor Relations web ...
Breaking Biology Technology:
(Date:2/2/2016)... 2, 2016 Checkpoint Inhibitors for Cancer ... Are you interested in the future of ... checkpoint inhibitors. Visiongain,s report gives those predictions to ... national level. Avoid falling behind in data ... and revenues those emerging cancer therapies can achieve. ...
(Date:2/1/2016)... NEW YORK , Feb. 1, 2016  Today, ... Heart Association (AHA) announced plans to develop a first ... cognitive computing power of IBM Watson. In the first ... disease, AHA, IBM (NYSE: IBM ), and Welltok ... metrics and health assessments with cognitive analytics, delivered on ...
(Date:1/25/2016)...  Glencoe Software, the world-leading supplier of image data ... provide the data management solution OMERO Plus for the ... Photo - http://photos.prnewswire.com/prnh/20160125/325328LOGO ... Phenotypic analysis measures the characteristics and behavior of ... states such as health and disease, the presence or ...
Breaking Biology News(10 mins):